Login / Signup
RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Jiajun Wang
Sihong Zhang
Ying Wang
Yanjun Zhu
Xianglai Xu
Jianming Guo
Published in:
BMC urology (2024)
RUNX3 pathway signature could be a potential predictive biomarker for IO/TKI treatment in advanced RCC, for both prognosis and treatment selection between IO/TKI and TKI monotherapy.
Keyphrases
</>
tyrosine kinase
epidermal growth factor receptor
renal cell carcinoma
advanced non small cell lung cancer
transcription factor
combination therapy
climate change
replacement therapy